<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Komajda, Michel</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ivabradine Added to Standard Therapy Improves Outcomes in Patients with Systolic HF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Results of the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial [SHIFT; ISRCTN70429960] indicate that when added to standard therapy, ivabradine reduced heart rate and improved outcomes in subjects with systolic heart rate as early as 3 months [Swedberg K et al. Lancet 2010].</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>